MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from marketable
securities
$225,076K
Net cash provided by
/ (used in)...
$26,663K
Canceled cashflow
$198,413K
Net change in cash
and cash...
-$24,946K
Canceled cashflow
$26,663K
Accounts receivable
-$51,200K
Stock-based compensation
(note 10e)
$28,034K
Prepaid expenses and
other current assets
-$6,509K
Amortization of intangible
assets (note 8)
$4,056K
Depreciation of property and
equipment (note 7)
$3,669K
Amortization and impairment
of operating lease...
$3,385K
Deferred income tax
expense (recovery)...
-$945K
Unrealized foreign
exchange loss (gain)
-$532K
Issuance of common stock
on exercise of...
$16,904K
Private placement (note
10a)
$4,988K
Issuance of common stock
through employee stock...
$1,425K
Purchases of marketable
securities
$196,061K
Acquisition of property and
equipment
$1,521K
Acquisition of intangible
assets
$831K
Net cash used in
operating activities
-$33,005K
Canceled cashflow
$98,330K
Net cash (used in) /
provided by financing...
-$18,559K
Effect of exchange rate
changes on cash and cash...
-$45K
Interest income
$13,354K
Canceled cashflow
$23,317K
Net loss
-$81,130K
Canceled cashflow
$13,354K
Accounts payable and
accrued liabilities
-$23,648K
Deferred revenue and
other consideration
-$23,170K
Operating lease
liabilities
-$3,342K
Income taxes payable
-$45K
Purchases of common stock
for retirement...
$41,695K
Deferred financing fees
$181K
Segment loss
-$56,790K
Stock-based compensation
expense
$28,034K
Depreciation and
amortization
$7,725K
Income tax (expense)
recovery, net
$1,376K
Other (expense)
income, net (note 12)
-$559K
Back
Back
Cash Flow
source: myfinsight.com
Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME)